Onyx Pharmaceuticals, Inc.
http://www.onyx-pharm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Onyx Pharmaceuticals, Inc.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Amylyx Steps Outside Neurodegenerative Disease With New Late-Stage Asset
The company outlined plans to develop newly acquired GLP-1 antagonist avexitide. CEOs Joshua Cohen and Justin Klee talked to Scrip about the strategy.
AnGes To Withdraw, Refile HGF Gene Therapy In Japan
If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.
AnGes To Withdraw, Refile HGF Gene Therapy In Japan
If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.
Company Information
- Other Names / Subsidiaries
-
- Proteolix, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice